News

Oncolytics Biotech Inc. Achieves Nasdaq Compliance Milestone

Oncolytics Biotech Inc. Achieves Nasdaq Compliance Milestone

Oncolytics Biotech Inc. Achieves Nasdaq Compliance Milestone

Oncolytics Biotech Inc. (Nasdaq: ONCY), a pioneering clinical-stage company that specializes in innovative immunotherapy for cancer treatment, has received a significant update regarding its stock compliance status. After previously facing potential delisting, Oncolytics has successfully regained compliance with the minimum bid price requirement mandated by Nasdaq.

Understanding the Compliance Situation

The company received a formal notice from Nasdaq’s Listing Qualifications Department indicating that it met the necessary criteria regarding its common shares. Specifically, this compliance demonstrates that Oncolytics' stock has maintained a closing bid price of at least $1.00 per share for the specified period of 10 consecutive business days. This milestone is crucial for maintaining trading on the Nasdaq Capital Market under the ticker symbol "ONCY."

History Leading to Compliance

Earlier this year, Oncolytics was alerted by Nasdaq about the failure to uphold the required minimum bid price, which is set at US$1.00 for 30 consecutive days. The recent Compliance Notice confirms that the Company addressed this issue effectively, with share prices reaching above this threshold from early July through late July. This achievement allows Oncolytics to continue its operations without interruption and reassures investors of its stability in the market.

About Oncolytics Biotech Inc.

As an innovative biotechnology entity, Oncolytics is at the forefront of developing a unique immunotherapeutic agent, pelareorep, delivered intravenously. This compound has shown promising results in clinical trials, particularly in the treatment of metastatic breast cancer and pancreatic cancer. Not only does pelareorep stimulate anti-cancer immune responses, but it also enhances the immune system’s ability to target and attack tumors effectively, thereby redefining treatment methodologies for various cancer types.

Clinical Trials and Future Directions

Oncolytics is actively conducting clinical trials that test the efficacy of pelareorep in combination with existing oncology therapies. The Company is making headway with registrational trials in the aforementioned cancer types and has received Fast Track designation from regulatory bodies, paving the way for potential breakthroughs in treatments.

Enhancing Patient Outcomes

The aim of Oncolytics is clear: to advance effective cancer treatments that improve patient outcomes and quality of life. By transforming immunotherapy strategies and efficiently incorporating pelareorep into treatment regimens, Oncolytics seeks to provide renewed hope to patients facing challenging diagnoses.

Company Values and Community Engagement

At its core, Oncolytics values not only innovative research but also a commitment to engagement with the larger healthcare community. This involves sharing important updates, developments, and breakthroughs, while maintaining transparency with stakeholders.

Conclusion

Regaining compliance with Nasdaq listing standards marks a significant turning point for Oncolytics Biotech Inc. The Company remains steadfast in its mission to innovate cancer treatment, offering new avenues of hope for patients. As it progresses toward clinical advancements, Oncolytics continues to solidify its reputation as a leader in biotechnology and cancer care.

Frequently Asked Questions

What does being in compliance with Nasdaq mean for Oncolytics?

Being in compliance means that Oncolytics has met the necessary stock price requirements to continue trading on the Nasdaq, showing stability and investor confidence.

What is pelareorep?

Pelareorep is an intravenous immunotherapeutic agent under development by Oncolytics, which has shown promise in treating various cancers, including breast and pancreatic cancers.

What are the benefits of Fast Track designation?

Fast Track designation accelerates the review process by regulatory authorities, enabling quicker access to promising treatments for patients and potential market entry.

How is Oncolytics contributing to cancer treatment research?

Oncolytics conducts clinical trials to explore the effectiveness of pelareorep combined with existing treatments, advancing new solutions in oncology.

Who can I contact for more information about Oncolytics?

For inquiries, you may reach out to Jon Patton, the Director of IR & Communication, or Mike Moyer at LifeSci Advisors for investor relations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
NEDHSA Amplifies Tobacco-Free Push with 2026 Smokeout

Updated Category News Views 87

2026 Great American Smokeout: A Fresh Push Against Tobacco NEDHSA is sticking to its guns with a tobacco-free campaign that’s got deep roots. The 2026 Great American Smokeout, on November 19, not only highlights past efforts but looks to stir more folks into healthier habits. Beyond the campaign glitz, it’s about dragging a century-long bad habit further into the...

Continue Reading
League's AI Launch: A New Era in Healthcare

Updated Category News Views 76

AI: Healthcare's Bold New Move Ah, here we go. Another tech jump in healthcare. This time it's the folks over at League, stirring the pot with some new AI gimmicks. They've slapped together what they call an 'AI Front Door' and an 'AI Care Companion'—part of their Forge by League platform. Now, if there's one thing we know, it's that the healthcare sector loves a good...

Continue Reading
Laboratory Filtration Market Expands to $6.55B by 2031

Updated Category News Views 108

A Niche Ready to Explode The laboratory filtration market isn't exactly the sort of thing that grabs headlines in the business section, but its growth is worth giving a second look. By 2031, this market's expected to hit $6.55 billion—up from $4.49 billion in 2026. If you think that's not impressive, chew on a 7.9% CAGR for the next few years. That's like watching your...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
First Time Homebuyer Tips for Southern Maryland Success

Updated Category News Views 94

Shaking Up First-Time Homebuyer Assumptions Ever hear that age-old nonsense about needing a fat stack of cash as a down payment before you can snag your first home? Yeah, turns out that's about as outdated as a rotary phone. Robin Cavallaro from RE/MAX Realty Group in Annapolis is setting the record straight for first-time buyers in Southern Maryland. Down Payment Myths...

Continue Reading
Lilly Endowment Boosts Military Families with $10M Grant

Updated Category News Views 70

A Game-Changer for Semper Fi & America's Fund Dive in, folks. What we've got here is a hefty chunk of change — $10 million to be precise — dropped into Semper Fi & America's Fund's lap by Lilly Endowment Inc. We're talking about a grant designed to shore up the long-term support system crafted for the brave souls in military families. It’s about time a significant...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 188

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 77

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Smart Mattress Market Expected to Reach USD 2.3 Billion Soon

Updated Category News Views 231

Overview of the Smart Mattress Market Growth Smart mattresses have emerged as key players in the bedding industry, shaped by the rising awareness of sleep's importance to overall health. With a current valuation of approximately USD 1.6 billion in 2023, the market is projected to reach USD 2.3 billion by 2032, growing at a compound annual growth rate (CAGR) of 3.7% in the...

Continue Reading
VyStar Foundation Celebrates Investment in Kennesaw State Education

Updated Category News Views 178

VyStar Credit Union and Kennesaw State Unveil VyStar Arena The anticipation surrounding the recent unveiling of VyStar Arena at Kennesaw State University is palpable, marking a significant achievement for both the university and VyStar Credit Union. This newly renovated arena will serve as the heart of athletic activities, hosting women's volleyball and men's basketball...

Continue Reading
Google Cloud and Verizon Transform Customer Engagement with AI

Updated Category News Views 599

Google Cloud and Verizon: Pioneering Customer Experience Innovations In a groundbreaking collaboration, Google Cloud has joined forces with Verizon to revolutionize customer service through innovative technology. This partnership leverages Google Cloud's generative AI to enhance the way Verizon serves its customers, resulting in significant improvements in customer...

Continue Reading
Celebrating the Holidays: Joyful Activities for Seniors

Updated Category News Views 161

Bringing Festive Cheer to Seniors This Holiday Season The holiday season is a special time for celebration, togetherness, and creating lasting memories, particularly for our seniors. Executive Home Care is dedicated to enhancing the holiday spirit for seniors by encouraging families and caregivers to engage in joyful activities that uplift and connect the loved ones in...

Continue Reading
Paragon Sports Revolution: NYC Store's Bold Overhaul

Updated Category News Views 32

Paragon Sports Redefines NYC's Retail Scene If you're thinking classic old guard can't innovate, take a gander at Paragon Sports. This 118-year-old New York cornerstone isn't just resting on its laurels as some ancient relic; they're breaking out the playbook for a fresh start in the Big Apple. In a bold move, they’ve decided to not only enhance their in-store...

Continue Reading